EQS-News
APONTIS PHARMA enters five-year distribution and marketing agreement with Novartis for two asthma medications and raises forecast
- APONTIS PHARMA partners with Novartis for asthma meds
- Forecast raised to EUR 50.7 million for 2024
- CEO sees deal as crucial for patient care in Germany
EQS-News: APONTIS PHARMA AG / Key word(s): Change in Forecast/Alliance
APONTIS PHARMA enters five-year distribution and marketing agreement with Novartis for two asthma medications and raises forecast
Information on upcoming events can be found at https://apontis-pharma.de/en/financial-calendar and the latest analyst assessments at https://apontis-pharma.de/en/share-price. APONTIS PHARMA AG is a leading pharmaceutical company specializing in Single Pill combinations in Germany. Single Pills combine two to three generic active ingredients in a single dosage form administered once a day. Single Pill therapies have been scientifically proven to significantly increase adherence and thus improve the treatment prognosis and quality of life of patients while reducing complications, mortality, and treatment costs. Consequently, Single Pill combinations are the preferred treatment option in numerous international treatment guidelines, including in the EU and Germany. APONTIS PHARMA has been developing, promoting, and distributing a broad portfolio of Single Pill combinations and other pharmaceutical products since 2013, with a special focus on cardiovascular diseases such as hypertension, hyperlipidemia, and secondary prevention. For additional information about APONTIS PHARMA, please visit www.apontis-pharma.de. Diskutieren Sie über die enthaltenen Werte |